.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Moodys
Express Scripts
Mallinckrodt
Covington
US Army
Merck
Johnson and Johnson
Medtronic
Harvard Business School

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021316

« Back to Dashboard

NDA 021316 describes ALTOPREV, which is a drug marketed by Covis Pharma Bv and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug. Additional details are available on the ALTOPREV profile page.

The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the lovastatin profile page.

Summary for 021316

Tradename:1
Applicant:1
Ingredient:1
Patents:3
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 021316

Medical Subject Heading (MeSH) Categories for 021316

Suppliers and Packaging for NDA: 021316

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316 NDA Shionogi Inc. 59630-628 59630-628-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59630-628-30)
ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316 NDA Shionogi Inc. 59630-629 59630-629-30 30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (59630-629-30)

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, EXTENDED RELEASE;ORALStrength10MG
Approval Date:Jun 26, 2002TE:RLD:No
Patent:► SubscribePatent Expiration:Dec 12, 2017Product Flag?Substance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Mar 23, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE
Patent:► SubscribePatent Expiration:Dec 12, 2017Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021316

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-002Jun 26, 2002► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-003Jun 26, 2002► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-004Jun 26, 2002► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-001Jun 26, 2002► Subscribe► Subscribe
Covis Pharma BvALTOPREVlovastatinTABLET, EXTENDED RELEASE;ORAL021316-003Jun 26, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
AstraZeneca
Julphar
Farmers Insurance
Queensland Health
Johnson and Johnson
Argus Health
Citi
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot